Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A00134-39 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The pandemic forced us to develop home follow-up for patients with chronical diseases . In the same time, the new era of treatment for cystic fibrosis considerably improves the health of patients with this pathology.
This study aims to assess the satisfaction of patients and care providers for an alternated follow-up between tele-consults and in-hospital consults during one year for patients with cystic fibrosis treated by Kaftrio® since at least one year and stable.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Follow-up alternating between face-to-face consultation and teleconsultation every three months | Experimental | Patients of this arm will be followed alternating between face-to-face consultation and teleconsultation respecting the recommended frequency (every three months) during 12 months (M+3:teleconsultation - M+6:in-hospital consultation - M+9:teleconsultation - M+12 : in-hospital consultation) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Follow-up alternating between face-to-face consultation and teleconsultation every three months. | Other | The intervention will be an alternate follow-up every three months with:
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Patients and care providers satisfaction after one year of alternated follow-up (hospital Consults and Tele-consult) | Satisfaction of patients and care providers for the follow-up by the Client-Satisfaction-Questionnaire (CSQ-8 for patients and CSQ-3 for care-provider). For the CSQ-8 the minimum value is 8 and the maximum value is 32. There is three levels: Low satisfaction (8-20), medium satisfaction (21-26) and high satisfaction (27-32) . | Measured at inclusion and after one year of follow up. |
| Measure | Description | Time Frame |
|---|---|---|
| Patients and care providers satisfaction for tele consultation | Satisfaction of patients and care providers for tele-consults by telemedicine satisfaction Questionnaire (TSQ). The TSQ is a 14-item questionnaire in its final version, the questionnaire items are scored on a five-point scale, from 1 being strongly disagree to 5 being strongly agree.. The internal consistency of the TSQ was 0.93, which is considered acceptable and indicates strong correlations between the items that make up the scale. Predictive validity supported the conclusion that the TSQ measured patient satisfaction with telemedicine (Pearson's correlation coefficient (r=0.45, P<0.05). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Thomas VIDAL | Contact | 478865671 | +33 | Thomas.vidal@chu-lyon.fr |
| Isabelle Durieu, Pr | Contact | isabelle.durieu@chu-lyon.fr |
| Name | Affiliation | Role |
|---|---|---|
| Thomas VIDAL | adult cystic fibrosis centre Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Lyon Sud | Recruiting | Pierre-Bénite | 69 495 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Measured after tele-consult (at 6 month M+6 and at 12 month M+12) |
| Comparison between FEV1 measured at the department's respiratory functional exploration center and FEV1 measured with the Spirobank ® during the same in-hospital visit. | Comparison between FEV1 measured at the department's respiratory functional exploration center and FEV1 measured with the Spirobank ® during the same in-hospital visit in order to check that the difference between the two values does not exceed the margin of error of 5%. | At inclusion, 6month and 12 month |
| effect on Patients and care providers quality of life | Quality of life of patients by Cystic fibrosis questionnaire revised(CFQ-R). The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for children and adults with CF. The CFQ-R contains both general and CF-specific scales. The CFQ-R was administered at Days 0, 14, 28, and 42. The endpoint was change in respiratory symptoms (e.g., coughing, congestion, wheezing) from Day 0 (baseline), assessed with the CFQ-R RSS (score range: 0-100; higher scores indicating fewer symptoms, higher health-related quality of life, or better functioning). Baseline CFQ-R RSS and age group (<18 vs. >=18 years) were included as covariates in the analysis. | Measured at inclusion and after one year |
| effect on Patients FEV1 (Forced expiratory volume) | FEV1 measured in start and at the end of the study | Measured at inclusion and after one year |
| effect on Patients antibiotic cure number | Antibiotic cure during one year before start and after one year of the study | Measured at inclusion and after one year |
| effect on patient's weight | Weight measured in start and at the end of the study | Measured at inclusion and after one year |
| Effect on Patients call and mail to CF center | Number of calls and mails to CF center during one year before start and after one year of the study | Measured at inclusion and after one year |
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |
Not provided
Not provided